¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"low malignant potential tumor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • polarizing potential
    ºÐ±ØÀüÀ§, Æí±¤ÀüÀ§
  • polyphasic action potential
    ´Ù»óȰµ¿ÀüÀ§
  • potential
    1. ÀüÀ§ 2. °¡´É¼º, ÀáÀç·Â
  • potential acuity meter
    ÀáÀç½Ã·ÂÃøÁ¤±â
  • potential barrier
    ÀüÀ§À庮
  • potential difference
    ÀüÀ§Â÷
  • potential doubling time
    ÀáÀç¹è°¡½Ã°£
  • potential energy
    ÀüÀ§¿¡³ÊÁö, À§Ä¡¿¡³ÊÁö
  • potential gradient
    ÀüÀ§±â¿ï±â, ÀüÀ§Â÷
  • potential surface
    ÀüÀ§¸é
  • potential trauma
    ÀáÀç¿Ü»ó
  • pathogenic potential
    ¹ßº´´É
  • phase boundary potential
    »ó°èÀüÀ§
  • receptor potential
    ¼ö¿ëüÀüÀ§
  • redox potential
    »êȭȯ¿øÀüÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • miniature end plate potential
    ²¿¸¶Á¾¸»ÆÇÀü¾Ð, ¹Ì¼¼Á¾¸»ÆÇÀüÀ§
  • monophasic action potential
    ´Ü»óȰµ¿ÀüÀ§
  • motor evoked potential
    ¿îµ¿½Å°æÀ¯¹ßÀüÀ§
  • myotonic potential
    ±ÙÀ°±äÀåÀüÀ§
  • potential acuity meter
    ÀáÀç½Ã·ÂÃøÁ¤±â
  • near field potential
    ±ÙÁ¢ºÎÀ§È°µ¿ÀüÀ§
  • negative potential
    À½ÀüÀ§
  • nerve action potential
    ½Å°æÈ°µ¿Àü¾Ð
  • oscillatory potential
    Áøµ¿¼ÒÆÄÀüÀ§
  • oxidation-reduction potential
    »êȭȯ¿øÀüÀ§
  • potential
    ÀüÀ§, °¡´É¼º, ÀáÀç·Â
  • pacemaker potential
    ½É¹ÚÁ¶À²±âÀü¾Ð, ÇâµµÀâÀÌÀüÀ§, ÆäÀ̽º¸ÞÀÌÄ¿ÀüÀ§
  • pathogenic potential
    ¹ßº´´É
  • phase boundary potential
    »ó°èÀüÀ§
  • plate potential
    ÆÇÀüÀ§
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • malignant hemocytoblastoma
    ¾Ç¼ºÇ÷±¸¸ð¼¼Æ÷Á¾(?Ì´Ë´ËÎËṴ̡̂).
  • malignant hidradenoma
    ¾Ç¼º ÇѼ±Á¾
  • malignant histiocytoma
    ¾Ç¼º Á¶Á÷±¸Á¾
  • malignant histiocytosis
    ¾Ç¼ºÁ¶Á÷±¸Áõ(¡­ðÚòÄϹñø).
  • malignant histiocytosis
    ¾Ç¼º Á¶Á÷±¸Áõ
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾ÐÁõ(ÊÙË­Ì´ËâÌ¡).
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾ÐÁõ(¡­ÍÔúìäâñø).
  • malignant hyperthermia
    ¾Ç¼º°í¿­(Áõ).
  • malignant hyperthermia syndrome
    ¾Ç¼º°í¿­ÁõÈıº.
  • malignant hyperthermia syndrome
    ¾Ç¼º°í ¿­ÁõÈıº.
  • malignant jaundice
    ¾Ç¼ºÈ²´Þ(¡­üÜÓ¸).
  • malignant lentigo
    ¾Ç¼º ÈæÀÚ
  • malignant lymphoma
    ¾Ç¼º¸²ÇÁÁ¾(¡­ðþ).
  • malignant lymphoma
    ¾Ç¼º¸²ÇÁÁ¾(¡­ðþ)
  • malignant lymphoma
    ¾Ç¼º¸²ÇÁÁ¾(?Ì¡).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
NMS Neuroleptic Malignant Syndrome
CMM cell-mediated mutagenesis; cutaneous malignant melanoma
FMN first malignant neoplasm; flavin mononucleotide; frontomaxillonasal [suture]
HCMM hereditary cutaneous malignant melanoma
MA malignant arrhythmia; management and administration; mandelic acid; masseter; Master of Arts; matern...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
CMAP Compound motor action potential
CMAP Compound muscle action potential
CNAP Compound nerve action potential
CSEP Cortical somatosensory evoked potential
ERP early receptor potential
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • nasopharyngeal tumor
    ºñ ÀεΠÁ¾¾ç
  • nerve tumor
    ½Å°æ Á¾¾ç
  • neuroectodermal tumor
    ½Å°æ ¿Ü¹è¿± Á¾¾ç
  • neuroendocrine tumor
    ½Å°æ ³»ºÐºñÁ¾
  • neuroglial tumor
    ½Å°æ±³ Á¾¾ç
  • nevoid tumor
    ¸ð¹Ý¾ç Á¾¾ç
  • nonclassifed tumor
    ºÐ·ùµÇÁö ¾Ê´Â Á¾¾ç
  • odontogenic mixed tumor
    Ä¡¿ø È¥ÇÕ Á¾¾ç
  • ovarian tumor
    ³­¼Ò Á¾¾ç
    ³­¼Ò¿¡¼­ »ý±â´Â Á¾¾ç. ³­¼Ò´Â ÀÎüÀÇ Àå±â Áß¿¡¼­ °¡Àå ¸¹Àº Á¾·ùÀÇ Á¾¾çÀÌ ¹ß»ýÇÏ´Â ±â°üÀÌ¸ç ±× ºÐ·ù¹ýµµ ´Ù¾çÇØ, ¿©·¯ °¡Áö À̸§À¸·Î ºÒ¸°´Ù. ÀÓ»óÀûÀ¸·Î´Â ¾ç¼º, ¾Ç¼º, Áß°£¼ºÀÇ ¼¼ °¡Áö·Î ´ëº°µÇÁö¸¸ °¨º°ÀÌ °ï¶õÇÑ °æ¿ìµµ ÀÖ´Ù. ´ëü·Î Ãæ½ÇºÎ°¡ ÀüÇô ¾ø´Â ¼ø³¶Æ÷¼ºÀÇ °ÍÀ» ³¶Æ÷¼º Á¾¾çÀ̶ó ÇÏ¸ç ¾ç¼ºÀÌ´Ù. Ãæ½ÇºÎ·Î µÇ¾î ÀÖ´Â °æ¿ì¸¦ Ãæ½Ç¼º Á¾¾çÀ̶ó Çϸç, ³¶Æ÷ºÎ¿Í Ãæ½ÇºÎ°¡ ¼¯¿© ÀÖ´Â °æ¿ì¸¦ ¹ÝÃæ½Ç¼º Á¾¾çÀ̶ó Çϴµ¥ ÀÌ µÎ °¡Áö¸¦ ÇÕÃļ­ Ãæ½Ç¼º Á¾¾çÀ̶ó ÇÑ´Ù.
  • papillomatous tumor
    À¯µÎ¼º Á¾¾ç
  • paratesticular tumor
    °íȯ¹æ Á¾¾ç
  • pea-size tumor
    °­³²Äá Å©±âÀÇ Á¾¾ç
  • peripapillary tumor
    À¯µÎ ÁÖÀ§ Á¾¾ç
  • primary tumor
    ¿ø¹ß Á¾¾ç
  • pulmonary sulcus tumor
    Æó±¸ Á¾¾ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 11
malignant teratoma <oncology, tumour> A collection of cancerous cells which form cysts that contain one or more of the three primary embryonic germ layers: skin, hair or teeth.
(27 Sep 1997)
malignant tertian fever <infectious disease> A tropical parasitic disease caused by one of the genus Plasmodium and carried by infected mosquitoes of the genus Anopheles. This parasite uses red blood cells to complete its reproductive cycle.
Common symptoms of an attack include high fever, chills, sweats and body aches.
(27 Sep 1997)
malignant tertian malaria <infectious disease> A tropical parasitic disease caused by one of the genus Plasmodium and carried by infected mosquitoes of the genus Anopheles. This parasite uses red blood cells to complete its reproductive cycle.
Common symptoms of an attack include high fever, chills, sweats and body aches.
(27 Sep 1997)
malignant tertian malarial parasite A species of protozoa that is the causal agent of falciparum malaria (malaria, falciparum). It is most prevalent in the tropics and subtropics.
(12 Dec 1998)
malignant tumour A mass of cancer cells. These cells have uncontrolled growth and will invade surrounding tissues and spread to distant sites of the body, setting up new cancer sites, a process called metastasis.
(09 Oct 1997)
Rhodesian malignant theileriosis A highly pathogenic protozoan disease of cattle in Zimbabwe caused by Theileria parva bovis and transmitted by the tick Rhipicephalus appendiculatus.
See: kaodzera.
Tropical theileriosis, a highly pathogenic protozoan disease of cattle in northern Africa, southern Europe, the Near and Middle East, and central Asia; caused by Theileria annulata and transmitted by ticks of the genus Hyalomma.
Synonym: Mediterranean theileriosis.
(05 Mar 2000)
midline malignant reticulosis granuloma Destruction of the nasal septum, hard palate, lateral nasal walls, paranasal sinuses, skin of the face, orbit and nasopharynx by an inflammatory infiltrate with atypical lymphocytic and histiocytic cells; presumably a form of lymphoma in most cases.
An obsolete term for polymorphic reticulosis.
Synonym: granuloma gangrenescens, malignant granuloma, midline malignant reticulosis granuloma.
(05 Mar 2000)
mixed tumour, malignant A malignant tumour composed of more than one type of neoplastic tissue.
(12 Dec 1998)
pleural effusion, malignant Presence of fluid in the pleural cavity as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.
(12 Dec 1998)
histiocytic disorders, malignant Distinctive neoplastic disorders of histiocytes. Included are acute monocytic leukaemias, malignant histiocytosis (histiocytosis, malignant), and true histiocytic lymphomas.
(12 Dec 1998)
histiocytosis, malignant A rare, usually rapidly progressive disorder, characterised by abrupt onset, fever, weight loss, hepato-splenomegaly, pancytopenia, and lymphadenopathy.
(12 Dec 1998)
hypertension, malignant Severe hypertension characterised by papilledema and necrosis of small arteries and arterioles. The diastolic pressure is generally greater than 130 mm hg.
(12 Dec 1998)
neuroleptic malignant syndrome <syndrome> This describes the combination of catatonic rigidity, stupor, unstable blood pressure, fever, profuse sweating, sweating and incontinence as a reaction to antipsychotic agents (phenothiazines) in therapeutic doses.
Origin: Gr. Lepsis = a taking hold
(27 Sep 1997)
desmoplastic malignant melanoma <tumour> A melanoma with marked fibrosis surrounding atypical spindle-shaped melanocytes in the dermis.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
ÅëÇÕ°Ë»ö ¿Ï·á